[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Aim Immunotech Inc (AIM)

Aim Immunotech Inc (AIM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,455
  • Shares Outstanding, K 14,564
  • Annual Sales, $ 90 K
  • Annual Income, $ -13,960 K
  • EBIT $ -10 M
  • EBITDA $ -8 M
  • 60-Month Beta 1.24
  • Price/Sales 40.30
  • Price/Cash Flow N/A
  • Price/Book 0.94
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -5.13
  • Most Recent Earnings $-0.69 on 05/15/26
  • Next Earnings Date 08/13/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.37
  • Number of Estimates 1
  • High Estimate $-0.37
  • Low Estimate $-0.37
  • Prior Year $-3.68
  • Growth Rate Est. (year over year) +89.95%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.2100 +12.95%
on 05/20/26
0.6930 -65.77%
on 05/18/26
-0.2888 (-54.90%)
since 04/22/26
3-Month
0.2100 +12.95%
on 05/20/26
1.6200 -85.36%
on 03/18/26
-0.8128 (-77.41%)
since 02/20/26
52-Week
0.2100 +12.95%
on 05/20/26
20.3500 -98.83%
on 07/28/25
-8.2628 (-97.21%)
since 05/22/25

Most Recent Stories

More News
AIM ImmunoTech Announces $2.4 Million Financing, Including Concurrent Registered Direct Offering and Private Placement

OCALA, Fla., May 20, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc . (NYSE American: AIM)  (“AIM” or the “Company”, today announced that it has entered into definitive agreements for a registered...

AIM : 0.2372 (-2.59%)
AIM ImmunoTech Announces Significant Increase in Stockholder Equity and Extension of Promissory Note Maturity Date to June 2027, Enhancing Financial Flexibility and Supporting Strategic Clinical Priorities

OCALA, Fla., May 19, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM)  (“AIM” or the “Company”) today announced a significant increase in stockholder equity and that the...

AIM : 0.2372 (-2.59%)
AIM ImmunoTech Posts Virtual Investor Key Opinion Leader Segment Spotlighting Ampligen Breakthrough Data in Pancreatic Cancer

Positive Data from Named Patient Program and Positive Interim Data from Ongoing Phase 2 Clinical Trial Segment featuring Professor Doctor Casper H.J. van Eijck, Professor and Pancreato-biliary...

AIM : 0.2372 (-2.59%)
AIM ImmunoTech, Inc. Announces Exercise of Warrants for Approx. $4.2 Million in Gross Proceeds

OCALA, Fla., May 08, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech, Inc. (NYSEAM:AIM) (“AIM ImmunoTech” or the “Company”), a late-stage biotechnology company focused on the discovery and development...

AIM : 0.2372 (-2.59%)
AIM ImmunoTech Announces 50% Objective Response Rate (ORR) in UPMC Recurrent Ovarian Cancer Phase 2 Clinical Trial, Suggesting Breakthrough Combination Potential

OCALA, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM)  (“AIM” or the “Company”) today announced the Final Primary Endpoint Report on Objective Response...

AIM : 0.2372 (-2.59%)
AIM ImmunoTech Enters Pivotal Value Inflection Phase with Planned Phase 3 Study of Ampligen® in Pancreatic Cancer, Backed by Positive Clinical Signals, Orphan Drug Status, and Global IP

Company to participate in Live Virtual Investor Closing Bell segment today, April 16 th  at 4:00 PM ET ; Register for the event  here OCALA, Fla., April 16, 2026 (GLOBE NEWSWIRE) --...

AIM : 0.2372 (-2.59%)
AIM ImmunoTech Provides Routine Update on Annual Filings

OCALA, Fla., April 13, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM)  (“AIM” or the “Company”) today advised that its audited consolidated financial statements for the...

AIM : 0.2372 (-2.59%)
AIM ImmunoTech to Participate in Live Virtual Investor Closing Bell Event

Live video webcast with Tom Equels, Chief Executive Officer of AIM ImmunoTech, on Thursday, April 16 th  at 4:00 PM ET   Register for the event here OCALA, Fla., April 09, 2026 (GLOBE...

AIM : 0.2372 (-2.59%)
accesso® Acquires Dexibit®, Establishing the First Cross Platform AI and Analytics Platform for Visitor Attractions

Acquisition launches accesso Intelligence SM , connecting guest and operator data, insight and action across the entire operation

AIM : 0.2372 (-2.59%)
accesso® Acquires Dexibit®, Establishing the First Cross Platform AI and Analytics Platform for Visitor Attractions

Acquisition launches accesso Intelligence SM , connecting guest and operator data, insight and action across the entire operation

AIM : 0.2372 (-2.59%)

Business Summary

AIM ImmunoTech Inc. is an immuno-pharma company. It is focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency diseases. The company's flagship products include Ampligen(R), Rintamod(R) and Alferon N Injection(R) which are in clinical stage. AIM...

See More

Key Turning Points

3rd Resistance Point 0.2648
2nd Resistance Point 0.2564
1st Resistance Point 0.2468
Last Price 0.2372
1st Support Level 0.2288
2nd Support Level 0.2204
3rd Support Level 0.2108

See More

52-Week High 20.3500
Fibonacci 61.8% 12.6565
Fibonacci 50% 10.2800
Fibonacci 38.2% 7.9035
Last Price 0.2372
52-Week Low 0.2100

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.